Abnormal steroidogenesis and aromatase activity in preeclampsia

Area of Science:

• Reproductive endocrinology
• Maternal-fetal medicine
• Biomarker discovery

Background:

• Estrogens and progesterone are vital for blood vessel formation and dilation.
• Placental aromatase deficiency is noted in preeclampsia (PE) at delivery.
• Abnormal steroidogenesis may precede clinical PE diagnosis.

Purpose of the Study:

• To determine if circulating steroid profiles are altered in early gestation (24-29 weeks) in women who later develop PE.
• To compare these profiles with those in women with small for gestational age (SGA) without PE.

Main Methods:

• Plasma steroid profiling using gas chromatography/mass spectrometry in 90 nulliparous women (25 PE, 25 SGA, 40 controls).
• Measurement of placental growth factor and soluble fms-like tyrosine kinase-1.
• Evaluation of placental aromatase expression.

Main Results:

• Women with PE showed lower estrone/androstenedione ratios and decreasing estradiol/estrone trends.
• Lower estriol levels were found in the SGA group.
• Both PE and SGA groups had higher 20α-dihydroprogesterone (20α-DHP) and 20α-DHP/progesterone ratios.
• Lower pregnenolone sulfate levels were observed in the PE group.
• Decreased placental aromatase expression was noted in the PE group.

Conclusions:

• Preeclampsia is associated with specific steroidogenesis dysregulation much earlier than diagnosis.
• These steroid profile alterations may serve as potential early biomarkers for PE.